Sabra Health Care REIT, Inc. (SBRA)
NASDAQ: SBRA · Real-Time Price · USD
16.72
-0.19 (-1.12%)
Feb 4, 2025, 4:00 PM EST - Market closed
Sabra Health Care REIT Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Sabra Health Care REIT stock have an average target of 19.17, with a low estimate of 17 and a high estimate of 20. The average target predicts an increase of 14.65% from the current stock price of 16.72.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sabra Health Care REIT stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 5 | 5 | 3 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 3 | 3 | 3 | 3 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 9 | 9 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy → Hold Downgrades $18 → $17 | Strong Buy → Hold | Downgrades | $18 → $17 | +1.67% | Jan 17, 2025 |
| JMP Securities | JMP Securities | Hold → Buy Upgrades $20 | Hold → Buy | Upgrades | $20 | +19.62% | Jan 7, 2025 |
| Mizuho | Mizuho | Buy → Hold Downgrades $20 | Buy → Hold | Downgrades | $20 | +19.62% | Dec 5, 2024 |
| Scotiabank | Scotiabank | Hold Maintains $17 → $18 | Hold | Maintains | $17 → $18 | +7.66% | Oct 11, 2024 |
| Wells Fargo | Wells Fargo | Hold → Buy Initiates $16 → $20 | Hold → Buy | Initiates | $16 → $20 | +19.62% | Oct 1, 2024 |
Financial Forecast
Revenue This Year
701.97M
Revenue Next Year
753.87M
from 701.97M
Increased by 7.39%
EPS This Year
0.52
from 0.06
Increased by 765.76%
EPS Next Year
0.71
from 0.52
Increased by 38.28%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 741.6M | 830.1M | 930.7M | |||
| Avg | 702.0M | 753.9M | 799.7M | |||
| Low | 653.7M | 691.6M | 707.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 18.3% | 23.5% | |||
| Avg | - | 7.4% | 6.1% | |||
| Low | - | -1.5% | -6.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 0.55 | 0.78 | 0.85 |
| Avg | 0.52 | 0.71 | 0.77 |
| Low | 0.47 | 0.64 | 0.67 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 817.7% | 50.8% | 19.4% |
| Avg | 765.8% | 38.3% | 8.0% |
| Low | 690.6% | 23.7% | -6.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.